lumefantrine (Coartem) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy (Coartem tablets). Lumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. The most common adverse reactions of Coartem in adults are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.   NCATS

Chemistry

  • SMILES: CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1
  • InChIKey: DYLGFOYVTXJFJP-MYYYXRDXSA-N
  • Mol. Mass: 528.95
  • ALogP: 9.15
  • ChEMBL Molecules:
    lumefantrine  
    lumefantrine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( lumefantrine (Coartem), artemether - other name: artemether/ lumefantrine )

Alternative names

(±)-2,7-dichloro-9-((z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol | 2-dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(z)-ylidene]-9h-fluoren-4-yl}-ethanol | 2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9h-fluoren-4-yl]-ethanol | 9h-fluorene-4-methanol, 2,7-dichloro-9-((4-chlorophenyl)methylene)-alpha-((dibutylamino)methyl)-, (z)- | benflumelol | benflumetol | benflumetol, (-)-isomer | benflumetol, (+-)-isomer | benflumetol, (+)-isomer | dl-benflumelol | gnf-pf-1971 | lumefantrine | lumefrantrine

Organizations (197)

Research & Development (197)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (1)


 

Malaria

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Anemia (Phase 4)

Attention Deficit and Disruptive Behavior Disorders (Phase 4)

Body Weight (Phase 4)

Burkina Faso (Phase 4)

COVID-19 (Phase 3)

Drug Combinations (Phase 1/Phase 2)

Drug Interactions (Phase 4)

Fever (Phase 3)

Healthy Volunteers (Phase 1/Phase 2)

Helminthiasis (Phase 4)

HIV (Phase 4)

HIV Infections (Phase 4)

Infant Health (Phase 4)

Live Birth (Phase 4)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Malaria, Vivax (Phase 4)

Parasitemia (Phase 1)

Parasitic Diseases (Phase 1)

Pharmacokinetics (Phase 1/Phase 2)

Plasmodium falciparum (Phase 4)

Pregnancy (Phase 4)

Pregnancy Complications (Phase 4)

Premature Birth (Phase 4)

Protozoan Infections (Phase 1)

Schistosomiasis (Phase 4)

Schistosomiasis haematobia (Phase 2)

Stillbirth (Phase 4)

Tuberculosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 175
  • # of Trial Organizations: 197

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue